Health Care • Biotechnology: Pharmaceutical Preparations
$1.19 ▼ +0.00
(-0.42%)
MKT CAP: $51.9M • VOL: 177.2K
52W L $1 52W H $4
ROARABLE / RQD
D • 47/100
PIOTROSKI
4 / 9
GANX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $55.2K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.7M | -$20.4M | -$22.3M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$20.2M | -$20.4M | -$22.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.5M | -$18.9M | -$18.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$18.5M | -$18.9M | -$18.9M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.8M | $10.4M | — |
| Total Debt (Short + Long Term) | $300.1K | $328.3K | — |
| Total Stockholders' Equity | $18.6M | $7.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GANX.